Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Investor Presentation (June 2015)
36 slides from Suven Life Sciences's investor presentation, June 2015
Slide 1: Corporate Presentation
‘Suven Life Sciences Limited Corporate Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward- looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accu
Slide 3: Table of Contents
Table of Contents 1 Company Overview 2 Our Business Strategy 3 Our Financial Approach In search of new CNS therapies for better living 3
Slide 4: Company Overview
© | Company Overview
Slide 5: Business Model
Business Model Lead NCE based Formulation Clinical Supplies Chem lib/ comb identification / Lead Process Development & Pre - Clinical intermediates/ Manufacturing & chem hits characterization Optimisation Research Analytical APIs Packaging Services Contract Discovery Research And Research Manufactur
Slide 6: Mission
Mission Providing world-class R&D solutions for Global Life Science companies with quality, speed and in a cost effective manner In search of new CNS therapies for better living In search of new CNS therapies for better living 6
Slide 7: Our Evolution
Our Evolution Diverse and entrenched business Pioneer in CRAMS relationships Well integrated CRAMS and Proven ability and expertise Discovery services 1992 2003 2006 Complex In-house Initiation of CNS chemicals Drug programs with Discovery SUVN-502 as lead molecule 1989 1995 2005 2014 Generi
Slide 8: Company Overview
Company Overview Profitable and dividend paying since listing in 1995 on the NSE and BSE Established presence across o Contract Research And Manufacturing Services (CRAMS) - Leader and innovator for NCE based FY15 Revenue INR 529 Cr intermediates o Drug Discovery – Focused on CNS segment EBITDA
Slide 9: Key Business Highlights
Key Business Highlights The Company successfully raised IINR 200 Cr through a Qualified Institutions Placement (QIP) SUVN-G3031 for Cognition in Alzheimer’s Disease commenced Phase 1 Clinical Trial in USA under US-IND 123179 SUVN 502 completed Phase 1b clinical trial in USA and preparation is
Slide 10: Our Focus
Our Focus A full fledged bio-pharmaceutical solutions provider for global pharmaceutical companies 1 Focused on value addition in research and development 2 Investing in R&D over a decade specializing in CNS segment 3 NCE based CRAMS In search of new CNS therapies for better living 10
Slide 11: Business Drivers
Business Drivers Promising NCE Pipeline Industry relationships Execution Capabilities Strong Research Orientation Focus on driving quality research projects for clients In search of new CNS therapies for better living 11
Slide 12: Business Drivers
Business Drivers Promising NCE Pipeline Well qualified research team of 386 scientists of which 30 are PhD holders Industry Promising NCE research pipeline of 13 molecules relationships Undertaken 727 CRAMS projects since inception Execution Pioneer in CRAMS business – Capabilities research
Slide 13: Key Differentiators
Key Differentiators Suven Others Contract research Contract manufacturing Innovation led Process led Pioneer in CRAMS Followers & ‘Me-too’ segments Long term approach Short term approach High focus on NCEs Mostly generics Full spectrum services Mostly chemistry services In se
Slide 14: Business Drivers
Business Drivers Promising NCE State of the art facilities located Pipeline across Present across the entire CRAMS value chain – intermediates & APIs Industry Leveraging on research relationships capabilities to delivering NCE research An integrated research service Execution provider with u
Slide 15: Multi Location Facilities
Multi Location Facilities 300 CM reactors (93) 500L to 10 KL GL/SS GMP Intermediates Suryapet, Telangana, India Banjara Hills, Hyderabad, SUVEN Intermediate Mfg. India Facility Corporate Office Pashamylaram, Telangana, India SUVEN API & Formulation Facility 120 kL reaction volume 50L – 600
Slide 16: Business Drivers
Business Drivers Promising NCE Repeat business owing to long standing relationships with MNC Pipeline companies Long term commercial supply opportunity with the launch of Industry product by global sponsors relationships Working with innovator companies in developed markets having stringent re
Slide 17: Our Relationships
Our Relationships In search of new CNS therapies for better living 17
Slide 18: Business Drivers
Business Drivers Promising NCE Pipeline One of the few players in the world in the high value CNS segment research Industry Built strong intellectual capabilities in CNS segment since 2005. relationships Globally CNS is the second largest and fastest growing segment Execution A single succes
Slide 19: Suven Management Team
Suven Management Team Dr. Ramakrishna Nirogi VP Discovery Research Dr. Veera Reddy Arava VP Process Research Dr. Rajendiran Chinnapillay VP Process Research Dr. Padmakumar Kaimal VP Strategic Affairs Mr. Venkat Jasti Mr. Murthy VSN VP Technical Chairman & CEO Mr. Mohan Rao Mannem VP Business Develop
Slide 20: Our Business Strategy
Our @ 4 f Business : Strategy
Slide 21: The CRAMS Value Chain
The CRAMS Value Chain Suven’s position NCEs High margin Segment Under patent molecule Pre-generics (PARA IV) Medium margin Specialized generics, Specialty chemicals Low Low end generics, margin Older molecules, Fine chemicals In search of new CNS therapies for better living 21
Slide 22: Suven Revenue Profile
Suven Revenue Profile Solid sales growth with strong customer relationship Multi-year NCE based contract research for chemistry development for global sponsors. Entering into long term commercial supply agreements. Pipeline of 57 Phase 1, 52 phase 2, 1 phase 3 projects and 3 commercial stage
Slide 23: Suven Market Opportunity
Suven Market Opportunity Customer focused long standing relationships for various early phase to commercial chemistry development Geographically dispersed in global markets (USA, Europe, Japan, Korea, Israel) Niche products DMFs and ANDAs for regulated markets Growing market* opportunity for
Slide 24: Key Risks and Challenges
Key Risks and Challenges Sustaining long term relationships with innovator companies Potential price fluctuation/attrition Likely increase in competition from other Indian/global players Lack of disclosure due to CDAs Potential for lumpiness in revenues and profits 24 In search of new CNS
Slide 25: Key Takeaways
Key Takeaways Growth in CRAMS to fund drug discovery An integrated solutions provider for CNS in Asia. In-house drug discovery programs poised to take off with out-licensing opportunities In search of new CNS therapies for better living 25
Slide 26: Drug Discovery R&D - CNS
Drug Discovery R&D - CNS Why CNS? Central Nervous System (CNS) market is the Second Largest Therapeutic Category (15%) and it is one of the Fastest Growing segment Highly unmet medical need More than 200 compounds under development Challenges – High attrition during discovery and clinical
Slide 27: Market for CNS
Market for CNS Present market in CNS - $120 billion Market for Cognitive disorders – Over $30 billion 180 million worldwide suffer from CNS disorders that exhibit significant impairment of memory and other cognitive functions. An estimated 37 million people worldwide suffer from dementia, wi
Slide 28: Alzheimer's Disease
Alzheimer’s Disease Strong interest across pharma & biotech: Ongoing clinical programs across many MOAs: o Pfizer o Serotoneric o GSK o Cholinergic o Lilly o Glutamatergic o AstraZeneca o Glycine o BMS o GABA A o Merck o PDE o Roche o Histaminergic o Novartis o MAO-B o JNJ o Gamma secretase o Am
Slide 29: Partnering/Out-licensing Opportunities; Internal R&D Pipeline
Partnering/Out-licensing Opportunities Internal R&D Pipeline In search of new CNS therapies for better living 29
Slide 30: Partnering/Out-licensing Opportunities; Internal R&D Pipeline
Partnering/Out-licensing Opportunities Internal R&D Pipeline In search of new CNS therapies for better living 30
Slide 31: Exit Potential For SUVN-502
Exit Potential For SUVN-502 Lu AE58054 (Lundbeck, Otsuka) July RVT-101 (GSK, Axovant) December 2014 2013 o Bought post POC compound from GSK for $5 Mn in Dec 2014 and o $150 Mil upfront for phase II raised $315 Mn in June 2015. program Entering Phase 3 program Alzheimers program (CoMentis, Ast
Slide 32: Our Financial Approach
Our @ 4 f Financial : Approach
Slide 33: Financial Approach
Financial Approach R&D cost expensed out each year Prudent utilization of cash flows Low debt Shareholder value creation focus Consistently dividend paying In search of new CNS therapies for better living 33
Slide 34: Key Ratios FY15
Key Ratios FY15 PAT to Income 21% EBIDTA to Income 32% Cash Flow to Income 23% Pre - R&D EBITDA to Income 42% In search of new CNS therapies for better living 34
Slide 35: Financial Table – FY2015
Financial Table – FY2015 YoY Year ending Mar 31, 2015 FY15 FY14 Growth ` % of ` % of % Million Turnover Million Turnover Income 5,294.36 - 5,133.42 - 3.14 Pre-R&D EBITDA 2,240.02 42.31 2,700.36 52.60 (17.05) Pre-R&D EBITDA Margin 42.31% 0.00% 52.60% 0.00% 0.00% EBITDA 1,680.40 31.74 2,220.88 43.26 (
Slide 36: Contact
Contact Suven Life Sciences Ltd 6/F, Serene Chambers Road No. 5, Avenue 7 Banjara Hills Hyderabad 500034 Tel: +91 40 2354 1142 Fax: +91 40 2354 1152 info@suven.com vsunder@suven.com In search of new CNS therapies for better living 36
Suven Life Sciences — Investor Presentation (June 2015) on 6ix